. . . . . . "approved"@en . . . . . . . . . . . . . . "Oleovitamin D2"@en . . . . . . . . . . . . "50-14-6"@en . "Ercalciol"@en . "Ergocalciferol"@en . "Charles W. Bishop, Glenville Jones, Ronald L. Horst, Nicholas J. Koszewski, Joyce C. Knutson, Raju Penmasta, Robert M. Moriarty, Stephen Strugnell, Timothy A. Reinhardt, Liang Guo, Sanjay K. Singhal, Lei Zhao, \"Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2.\" U.S. Patent US5789397, issued March, 1992."@en . . "Vitamina D2"@en . "Humans and other mammals"@en . . . . "(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol"@en . "Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]"@en . . "LD₅₀ = 23.7 mg/kg (Orally in mice); LD₅₀ = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache."@en . . . "Ergocalciferol"@en . . . . "Activated ergosterol"@en . . "# DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15585789"@en . "Viosterol"@en . "(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol"@en . ">99.8%"@en . . . . . "Ergocalciferolum"@en . . . . . . . "Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits 2\u20135 times more activity than unactivated ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations. Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known. "@en . . . . . "nutraceutical"@en . . . . . . . . . . . . . . . . "19 to 48 hours (however, stored in fat deposits in body for prolonged periods)."@en . . "Vitamin D2"@en . . . . . . . . . . "Calciferol"@en . . . . "For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis)."@en . "Readily absorbed from small intestine (proximal or distal), requires presence of bile salts."@en . . . . . " "@en . . . . . . . . "(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol"@en . . .